BeOne Medicines (BEIGF) Non-Current Deferred Tax Liability (2016 - 2026)

BeOne Medicines (BEIGF) has 11 years of Non-Current Deferred Tax Liability data on file, last reported at $55.9 million in Q1 2026.

• Non-Current Deferred Tax Liability for Q1 2026 came in at $55.9 million, up 29.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $55.9 million (up 29.59% YoY), and the FY2025 annual result was $53.2 million, up 26.67% from the prior year.
• Non-Current Deferred Tax Liability climbed to $55.9 million in Q1 2026 per BEIGF's latest filing, from $53.2 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $55.9 million in Q1 2026 and troughed at $14.2 million in Q1 2022.
• A 5-year average of $27.7 million and a median of $16.4 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
• The sharpest annual moves came in 2023 and 2025: Non-Current Deferred Tax Liability slipped 18.18% in 2023, then surged 195.36% in 2025.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $24.6 million in 2022, then dropped by 18.18% to $20.1 million in 2023, then jumped by 108.9% to $42.0 million in 2024, then climbed by 26.67% to $53.2 million in 2025, then increased by 4.99% to $55.9 million in 2026.
• Business Quant data shows BEIGF's Non-Current Deferred Tax Liability at $55.9 million in Q1 2026, $53.2 million in Q4 2025, and $47.1 million in Q3 2025.